Par Pharmaceutical
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Par Pharmaceutical
Endo’s Par Opts For Authorized Generic As It Debuts Lubiprostone In US
Endo’s Par has introduced the first generic version of Mallinckrodt’s chronic idiopathic constipation medicine Amitiza, realizing the terms of a settlement agreement announced more than six years ago.
What’s Next? Five Things To Look Out For In October
In October, the period during which Mylan may complete its merger with Upjohn will begin, while the FDA will begin holding monthly stakeholder meetings ahead of the third iteration of the Generic Drug User Fee Amendments program, also known as GDUFA III.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Controlled Release
- Nasal
- Transdermal